10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 10.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,395 shares of the company’s stock after selling 4,143 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in 10x Genomics were worth $1,543,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of 10x Genomics by 4.2% in the third quarter. Vanguard Group Inc. now owns 8,903,517 shares of the company’s stock worth $367,270,000 after buying an additional 354,921 shares during the last quarter. Citigroup Inc. grew its position in 10x Genomics by 94.4% during the 3rd quarter. Citigroup Inc. now owns 10,951 shares of the company’s stock worth $452,000 after purchasing an additional 5,317 shares during the period. Comerica Bank purchased a new position in shares of 10x Genomics during the 3rd quarter valued at about $64,000. The Manufacturers Life Insurance Company lifted its holdings in shares of 10x Genomics by 28.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 98,027 shares of the company’s stock valued at $4,044,000 after buying an additional 21,524 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in shares of 10x Genomics by 460.4% in the third quarter. GSA Capital Partners LLP now owns 47,664 shares of the company’s stock worth $1,966,000 after buying an additional 39,158 shares during the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at 10x Genomics

In related news, CEO Serge Saxonov sold 4,660 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $44.00, for a total value of $205,040.00. Following the completion of the sale, the chief executive officer now owns 842,900 shares of the company’s stock, valued at $37,087,600. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other 10x Genomics news, CFO Justin J. Mcanear sold 1,865 shares of 10x Genomics stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $86,424.10. Following the transaction, the chief financial officer now directly owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 4,660 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $44.00, for a total transaction of $205,040.00. Following the completion of the sale, the chief executive officer now directly owns 842,900 shares of the company’s stock, valued at approximately $37,087,600. The disclosure for this sale can be found here. Insiders have sold a total of 16,959 shares of company stock worth $773,766 in the last ninety days. Insiders own 10.65% of the company’s stock.

Analyst Upgrades and Downgrades

TXG has been the subject of a number of analyst reports. Guggenheim assumed coverage on 10x Genomics in a report on Thursday, December 14th. They issued a “buy” rating and a $60.00 price target for the company. Wolfe Research assumed coverage on shares of 10x Genomics in a report on Wednesday, December 13th. They set an “outperform” rating and a $55.00 price target on the stock. Bank of America raised shares of 10x Genomics from an “underperform” rating to a “neutral” rating and lifted their price objective for the company from $36.00 to $54.00 in a report on Tuesday, December 12th. Barclays increased their target price on shares of 10x Genomics from $45.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Finally, Stifel Nicolaus cut their price target on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a research note on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $62.44.

Get Our Latest Stock Analysis on TXG

10x Genomics Stock Up 0.1 %

TXG opened at $36.31 on Tuesday. The company has a market cap of $4.33 billion, a PE ratio of -16.73 and a beta of 1.93. 10x Genomics, Inc. has a twelve month low of $33.79 and a twelve month high of $63.57. The company has a 50-day moving average price of $43.23 and a 200 day moving average price of $44.24.

10x Genomics (NASDAQ:TXGGet Free Report) last posted its quarterly earnings results on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The business had revenue of $183.98 million during the quarter, compared to analysts’ expectations of $182.73 million. During the same period in the prior year, the business posted ($0.15) earnings per share. The business’s quarterly revenue was up 17.8% on a year-over-year basis. As a group, sell-side analysts expect that 10x Genomics, Inc. will post -1.47 earnings per share for the current year.

10x Genomics Profile

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

See Also

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGFree Report).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.